There are companies who would move on B based on the current PII POC but the problem is, price and where does IPIX draw the line? It is appearing more and more likely that B is truly a platform drug and could have many of the same benefits as biologics without many of the nasty side effects...
What would be the value of a drug that competed with that class of medicine? There are currently more than 40 different biologic drugs with more than 1B in sales each. The total spend in 2015 on biologics was 208B.
My dream scenario would be to have Prurisol 2b be equal to or better than Otezla in efficacy, have a quick deal done in the 2-5B range (an outright sale) then use those funds to run a dozen or so powered PII trials for B and K. If that happens we may just be looking at the creation of the next BP.
Win or lose, we should know within 180 days if we're all fools or extremely lucky to have happened upon IPIX in its infancy.
Market Data 
Markets 
AI
